Halozyme Therapeutics, Inc. provides earnings guidance for the year 2024. For the period, the company expects Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.